본문 바로가기
KERD
논문KCI 등재

2019 대한부정맥학회 경피적심혈관중재술을 받는 심방세동 환자에서 항응고 치료 지침

Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention

이영수|박진규|김태훈|김준|이지현|정보영|이기홍|심재민|임우현|황유미
대한내과학회 (The Korean Association Of Internal Medicine)|2019.08|대한내과학회지 (The Korean Journal of Medicine)|제94권 제4호|pp. 330-342|DOI https://doi.org/10.3904/kjm.2019.94.4.330

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

GuidelineAnticoagulantsPercutaneous coronary interventionAtrial fibrillation
주제분류내과학

초록

The choice of an adequate antithrombotic regimen for atrial fibrillation patients undergoing emergent or elective percutaneous coronary intervention (PCI) should be based on the ischemic event and on the risk of bleeding. Recent randomized controlled trials have consistently demonstrated that dual antithrombotic therapeutic regimens, using non-vitamin K anticoagulants and clopidogrel, are superior to triple or dual therapy with warfarin and aspirin. This report incorporates findings of recent notable studies to provide concrete, clinically useful details and recommendations for bleeding risk assessment and optimal antithrombotic therapeutic strategies after PCI. In addition, we introduce guidelines for antithrombotic management after structural heart disease intervention.

Abstract

The choice of an adequate antithrombotic regimen for atrial fibrillation patients undergoing emergent or elective percutaneous coronary intervention (PCI) should be based on the ischemic event and on the risk of bleeding. Recent randomized controlled trials have consistently demonstrated that dual antithrombotic therapeutic regimens, using non-vitamin K anticoagulants and clopidogrel, are superior to triple or dual therapy with warfarin and aspirin. This report incorporates findings of recent notable studies to provide concrete, clinically useful details and recommendations for bleeding risk assessment and optimal antithrombotic therapeutic strategies after PCI. In addition, we introduce guidelines for antithrombotic management after structural heart disease intervention.

참고문헌 (59)

  1. Lip GY, "Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS), 2014, pp.35, 3155~3179
  2. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Europace, 18, pp.1609~1678 (2016)
  3. Chiang CE, "The 2017 focused update of the guidelines of the Taiwan Society of Cardiology(TSOC)and the Taiwan Hypertension Society(THS)for the management of hypertension", Acta Cardiol Sin, 33, pp.213~225 (2017)
  4. Ibanez B, "2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 39, pp.119~177 (2018)
  5. Steffel J, "The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation : executive summary", Europace, 20, pp.1231~1242 (2018)
  6. January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology, American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society[DOI]
  7. 정보영, "2018 Korean Guideline of Atrial Fibrillation Management", Korean Circulation Journal, 48(12), pp.1033~1080 (2018), 대한심장학회
  8. 이기홍, "2018 대한부정맥학회 심방세동 환자에서 항응고제의 적합한 선택 및 용량 권고안: 특수 상황과 고위험군 환자", 대한내과학회지, 93(2), pp.110~132 (2018), 대한내과학회
  9. 이정명, "2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침", 대한내과학회지, 93(2), pp.87~109 (2018), 대한내과학회
  10. 박예민, "2018 대한부정맥학회 NOAC 사용 지침: 특별한 상황에서의 약물 복용(관상동맥질환, 용량 혼동시, 심율동 전환, 뇌졸중 발생, 악성종양) 및 기타", 대한내과학회지, 94(1), pp.57~82 (2019), 대한내과학회[DOI]
  11. Lee HY, "Atrial fibrillation and the risk of myocardial infarction : a nation-wide propensity-matched study", Sci Rep, 7, pp.12716~ (2017)
  12. Park J, "Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention : a nationwide Korean population-based study", PLoS One, 14, pp.e0209593~ (2019)
  13. Park J, "Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention during 2-year follow-up, from a nationwide population study", Am J Cardiol, 123, pp.1921~1926 (2019)
  14. Lip GYH, "2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous cardiovascular interventions : a joint consensus document of the European Heart Rhythm Association(EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions(EAPCI), and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS), Asia-Pacific Heart Rhythm Society(APHRS), Latin America Heart Rhythm Society(LAHRS), and Cardiac Arrhythmia Society of Southern Africa(CASSA), 2019, pp.21, 192~193
  15. Proietti M, "Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention:The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry", Am Heart J, 190, pp.86~93 (2017)
  16. Lane DA, "Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes : results of the European Heart Rhythm Association survey", Europace (2019)[DOI]
  17. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
  18. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
  19. Lopes RD, "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", N Engl J Med, 380, pp.1509~1524 (2019)
  20. Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention(PCI)with stent placement : Rationale and design of the ENTRUST-AF PCI trial", Am Heart J, 196, pp.105~112 (2018)
  21. Golwala HB, "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention:a systematic review and meta-analysis of randomized clinical trials", Eur Heart J, 39, pp.1726~1735a (2018)
  22. Matsumura-Nakano Y, "Openlabel randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation", Circulation, 139, pp.604~616 (2019)
  23. Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
  24. Ohman EM, "Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes(GEMINI-ACS-1) : a double-blind, multicentre, randomised trial", Lancet, 389, pp.1799~1808 (2017)
  25. Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)
  26. Wiviott SD, "Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes : design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38(TRITON-TIMI 38)", Am Heart J, 152, pp.627~635 (2006)
  27. Wallentin L, "Ticagrelor versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 361, pp.1045~1057 (2009)
  28. Kowalewski M, "Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention", Int J Cardiol, 223, pp.186~194 (2016)
  29. Kolh P, "ESC", EACTS myocardial revascularization guidelines 2014, 2014, pp.35, 3235~3236
  30. Valgimigli M, "Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates", J Am Coll Cardiol, 65, pp.805~815 (2015)
  31. Urban P, "Polymer-free drug-coated coronary stents in patients at high bleeding risk", N Engl J Med, 373, pp.2038~2047 (2015)
  32. Garot P, "2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents", J Am Coll Cardiol, 69, pp.162~171 (2017)
  33. Varenne O, "Drug-eluting stents in elderly patients with coronary artery disease(SENIOR) : a randomised single-blind trial", Lancet, 391, pp.41~50 (2018)
  34. Byrne RA, "Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe : executive summary", Eur Heart J, 36, pp.2608~2620 (2015)
  35. Rodés-Cabau J, "Antithrombotic treatment in transcatheter aortic valve implantation : insights for cerebrovascular and bleeding events", J Am Coll Cardiol, 62, pp.2349~2359 (2013)
  36. Adams DH, "Transcatheter aortic-valve replacement with a self-expanding prosthesis", N Engl J Med, 370, pp.1790~1798 (2014)
  37. Gargiulo G, "Transcatheter aortic valve implantation versus surgical aortic valve replacement : a systematic review and meta-analysis", Ann Intern Med, 165, pp.334~344 (2016)
  38. Siontis GC, "Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials", Eur Heart J, 37, pp.3503~3512 (2016)
  39. Nijenhuis VJ, "Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation(TAVI)", Thromb Haemost, 113, pp.674~685 (2015)
  40. Gargiulo G, "Antithrombotic therapy in TAVI patients : changing concepts", EuroIntervention, 11(Suppl W), pp.W92~W95 (2015)
  41. Sannino A, "A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation", EuroIntervention, 12, pp.e1047~e1056 (2016)
  42. Gargiulo G, "Antithrombotic therapy after transcatheter aortic valve implantation : a new piece of the still unresolved puzzle", J Thorac Dis, 9, pp.4260~4265 (2017)
  43. Seeger J, "Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement", JACC Cardiovasc Interv, 10, pp.66~74 (2017)
  44. Capodanno D, "Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy", Int J Cardiol, 199, pp.319~325 (2015)
  45. Fauchier L, "Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting", Am J Cardiol, 118, pp.700~707 (2016)
  46. Guo Y, "Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation", Am J Med, 131, pp.185~192 (2018)
  47. Wang C, "Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients : a systematic review and meta-analysis", Oncotarget, 8, pp.109703~109711 (2017)
  48. Chao TF, "Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants : a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors", Thromb Haemost, 118, pp.768~777 (2018)
  49. Steffel J, "The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation", Eur Heart J, 39, pp.1330~1393 (2018)
  50. ACTIVE Writing Group of the ACTIVE Investigators, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events(ACTIVE W) : a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)
  51. Vranckx P, "Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial", Thromb Haemost, 114, pp.258~267 (2015)
  52. Niccoli G, "Heparin dose during percutaneous coronary intervention : how low dare we go", Heart, 88, pp.331~334 (2002)
  53. Hochholzer W, "Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention", Circulation, 111, pp.2560~2564 (2005)
  54. Roffi M, "2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 37, pp.267~315 (2016)
  55. Valgimigli M, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)", Eur Heart J, 39, pp.213~260 (2018)
  56. Hurlen M, "Warfarin, aspirin, or both after myocardial infarction", N Engl J Med, 347, pp.969~974 (2002)
  57. Hamon M, "Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease", J Am Coll Cardiol, 64, pp.1430~1436 (2014)
  58. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
  59. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)

관련 논문AI추천

2018 대한부정맥학회 심방세동 환자에서 NOAC 사용 지침: 출혈의 대처와 수술 전후 복약관리박준범, 박환철, 안진희, 이기홍, 이지현, 임우현, 임홍의, 정보영, 차명진, 최의근대한내과학회 · 대한내과학회지2019 · 제94권 제1호Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention곽순구, 양한모한국지질동맥경화학회 · 지질·동맥경화학회지2019 · 제8권 제1호2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침김준수, 김진배, 김태훈, 신승용, 엄재선, 이정명, 이지현, 임우현, 임홍의, 정보영, 차명진대한내과학회 · 대한내과학회지2018 · 제93권 제2호2021 대한부정맥학회 심방세동 환자의 뇌졸중 예방 관리 지침김진배, 신승용, 이기홍, 정보영대한내과학회 · 대한내과학회지2021 · 제96권 제4호2021 대한부정맥학회 심방세동 환자의 특수 임상 상황 환자군에서 ABC Pathway 치료 지침박예민, 유희태, 이대인, 임홍의, 정보영, 황유미대한내과학회 · 대한내과학회지2021 · 제96권 제4호2018 대한부정맥학회 심방세동 환자의 통합적 관리 지침김준, 김준수, 김진배, 박예민, 박준범, 박형욱, 안진희, 엄재선, 이대인, 이만영, 정보영대한내과학회 · 대한내과학회지2018 · 제93권 제4호

이 간행물의 다른 논문 (7건)

공통 데이터 모델과 분산연구망: 오딧세이 컨소시엄(Observational Health Data Sciences and Informatics, OHDSI) 연구사업박래웅pp. 309-314급성신손상의 원인과 치료오세원pp. 315-321췌장낭성종양의 최신 치료 가이드라인손병관, 정광현pp. 322-329Mycobacterium Abscessus 폐질환의 치료전병우, 고원중pp. 343-352두드러기의 분류와 진단예영민pp. 353-357
원문 보기